Loading stock data…
$3.79+0.10 (+2.71%)
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer.
Galectin Therapeutics Inc. in the Healthcare sector is trading at $3.79 with a market capitalization of $417M. Wall Street consensus targets $11.00 (1 analysts), implying a +190.2% move over the next 12 months. The stock is currently 47% below its 52-week high of $7.13, remaining 17.7% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.98M↑ | -$4.08M↓ | -$3.37M↑ | -$4.20M↑ | -$4.63M |
| Net Income | -$9.11M↓ | -$5.05M↑ | -$5.50M↑ | -$8.18M↓ | -$7.52M |
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which ...